Articles related to COGNITIVE HEALTH/MEMORY

Adding to the evidence that good nutrition supports healthy aging, this study shows that blood levels of certain saturated fatty acids, along with omega-6, -7 and -9 fatty acids, correlated with improved memory as well as larger frontal, temporal, parietal lobes.

Two-hundred sixteen (216) people with mild-to-moderate disease were treated with 100 mg simufilam tablets twice daily for 12 months. ADAS-Cog-11 score showed a “highly desirable” overall minimal decline in cognitive ability after one year. Simufilam is an oral small molecule designed to to prevent beta and tau amyloid clumping by correctong an altered form of filamin A.

Top-line data from an open-label Phase 2 study of 216 people with mild-to-moderate Alzheimer’s disease treated with simufilam tablets at 100 mg twice daily for a year revealed a minimal decline in cognitive ability overall, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11). Simufilam was found to be safe and well tolerated, and it alleviated depression and dementia-related behaviors in patients, which were two exploratory trial goals.

A study of nearly 10,000 adults aged 65 and older found that individuals with either complete tooth loss or diabetes had accelerated cognitive decline compared to those without the diseases. And decline was fastest for individuals 65-84 who had both conditions. The authors hypothesize a combination of nutritional deficiency and inflammation as playing a role.

Plasma P-tau217 significantly predicted longitudinal cognitive decline in both cohorts in this prognostic study of data from two preclinical AD cohort studies involving 171 cognitively unimpaired individuals with cerebrospinal fluid or positron emission tomographic measures of β-amyloid positivity. These findings imply that plasma P-tau217 could be used in clinical trials of novel disease-modifying treatments as a supplement to CSF or PET for participant selection.

In the study, 1,400 individuals were assessed multiple times between ages of 36 and 69 for level of physical activity. They were quantified as not active, moderately active, and most active. Cognition measurements in later life showed a dose-response relationship between sustained levels of physical activity and later-life cognition status.